Jpmorgan Chase & CO Morphic Holding, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 40,781 shares of MORF stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,781

Previous 60,347 32.42%

Holding current value

$1.39 Million

Previous $1.74 Million 17.62%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$26.64 - $40.31 $521,238 - $788,705	-19,566 Reduced 32.42%	40,781 $1.44 Million
Q4 2023 Feb 12, 2024	BUY	$19.95 - $31.0 $120,717 - $187,581	6,051 Added 11.14%	60,347 $1.74 Million
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $23,740 - $66,134	1,113 Added 2.09%	54,296 $1.24 Million
Q2 2023 Aug 11, 2023	BUY	$34.33 - $62.11 $638,503 - $1.16 Million	18,599 Added 53.78%	53,183 $3.05 Million
Q1 2023 May 18, 2023	BUY	$26.01 - $48.69 $890,920 - $1.67 Million	34,253 Added 10348.34%	34,584 $1.3 Million

Q1 2023 May 11, 2023	SELL	$26.01 - $48.69 $723,598 - $1.35 Million	-27,820 Reduced 98.82%	331 $12,000
Q4 2022 Feb 13, 2023	BUY	$24.14 - $30.37 $38,961 - $49,017	1,614 Added 6.08%	28,151 $753,000
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $46,927 - $70,444	2,111 Added 8.64%	26,537 $751,000
Q2 2022 Aug 11, 2022	BUY	$19.74 - $43.01 $80,499 - $175,394	4,078 Added 20.04%	24,426 $531,000
Q1 2022 May 11, 2022	BUY	$36.25 - $52.02 $138,656 - $198,976	3,825 Added 23.15%	20,348 $816,000
Q4 2021 Feb 10, 2022	SELL	$43.27 - $65.72 $499,076 - $758,014	-11,534 Reduced 41.11%	16,523 $783,000
Q3 2021 Nov 12, 2021	BUY	$53.61 - $67.5 $1.5 Million - $1.89 Million	28,057 New	28,057 $1.59 Million

Others Institutions Holding MORF

# of Institutions

142

Shares Held

37.9M

Call Options Held

13.5K

Put Options Held

190K

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $1.31B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Morphic Holding, Inc. Transaction History